Drug that cuts risk of breast cancer returning is approved for use in England
Up to 4,000 patients a year with early stage of disease could receive ribociclib, but charities want wider access to drugThousands of women with early breast cancer could be offered a drug to stop the cancer returning, after the medicines watchdog approved its use in England.Up to 4,000 patients a year could be given ribociclib alongside hormone therapy, for hormone receptor-positive, HER2-negative early breast cancer, which despite initial treatment has a higher risk of returning.Cancer present in at least four lymph nodes.Cancer present in one to three lymph nodes that is either grade 3 (more advanced), or has a primary tumour at least 5cm in size. Continue reading...
Up to 4,000 patients a year with early stage of disease could receive ribociclib, but charities want wider access to drug
Thousands of women with early breast cancer could be offered a drug to stop the cancer returning, after the medicines watchdog approved its use in England.
Up to 4,000 patients a year could be given ribociclib alongside hormone therapy, for hormone receptor-positive, HER2-negative early breast cancer, which despite initial treatment has a higher risk of returning.
Cancer present in at least four lymph nodes.
Cancer present in one to three lymph nodes that is either grade 3 (more advanced), or has a primary tumour at least 5cm in size. Continue reading...
